ADVENTRX logo
Company Products Clinical Trials Partners Investors News Publications Contact
Company

MISSION & STRATEGY

CLINICAL & REGULATORY STRATEGY

COMMERCIALIZATION

TEAM

ADVENTRX Pharmaceuticals is a development-stage specialty pharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of cancer. The Company seeks to improve the performance of existing drugs by addressing limitations associated principally with their safety and use.

Our lead product candidates, ANX-530 (vinorelbine injectable emulsion), or Exelbine™, and ANX-514 (docetaxel lyophilized emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs.






An interview with ADVENTRX Chief Executive Officer Brian M. Culley was featured in the October 19th issue of The Wall Street Transcript.

COMPANY | PRODUCTS | CLINICAL TRIALS | PARTNERS | INVESTORS | NEWS | PUBLICATIONS | CONTACT
HOME | CAREERS | SEARCH | SITE MAP | HELP | TERMS AND CONDITIONS | PRIVACY STATEMENT
© Copyright 2009 ADVENTRX Pharmaceuticals

Search Careers Back to homepage